Predicting diabetic retinopathy progression

Article

A diabetic retinopathy (DR) progression biomarker software has been developed with the research institute AIBILI (Association for Biomedical Research and Innovation in Light and Image) and Critical Health.

A diabetic retinopathy (DR) progression biomarker software has been developed with the research institute AIBILI (Association for Biomedical Research and Innovation in Light and Image) and Critical Health. It will be officially launched at this week's Euretina congress in Nice.

The RetmarkerDR is able to calculate and provide important ratios regarding Microaneurysm Turnover (formation and disappearance rates) which are key indicators of progression of retinal diseases like Diabetic Retinopathy. The solution uses an advanced proprietary co-registration algorithm which allows practioners to correctly overlap the retinographies (colour fundus photographs) and complements it with a state-of-the-art Microaneurysm (MA) detector to calculate the referred ratios.

The software identifies each microaneurysm as a single entity in a specific location, with identifiable coordinates, allowing for access to valuable information, such as:

• Number of microaneurysms at each visit;
• Number of new microaneurysms since last visit;
• Number of micronaneurysms that suffered oclusion;
• Cumulative number of microaneurysms;
• Microaneurysm formation rate;
• Microaneurysm disappearance rate.

Professor Conceiçäo Lobo, a leading ophthalmologist and researcher from the University Hospital of Coimbra, in Portugal, says: "According to our research, where we analysed different type 2 diabetic patients with nonproliferative retinopathy, Microaneurysm Turnover was a key factor for the classification in different phenotypes and appears to be a good predictor of progression to Clinically Significant Macular Edema (CSME)."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.